Tus kws kho mob
P43R1-16 Updated: Third Party Payments of Premium and/or Cost-Sharing
Hnub Tim pib siv tau lub khoos kas: Lub Kaum Ib Hlis Ntuj Tim 01, 2016
Tshawb Nrhiav
Nthuav pom cov txiaj ntsig tshwm sim 3051 - 3060 ntawm 4138
Tus kws kho mob
P6-17 A New Drug, Emflaza (deflazacort), Will Require Prior Authorization
Hnub Tim pib siv tau lub khoos kas: Lub Ob Hlis Ntuj Tim 27, 2017
Tus kws kho mob
P46-16 Changes in Medical Policy IV-87 Spinal Fusion: Lumbar
Hnub Tim pib siv tau lub khoos kas: Lub Cuaj Hlis Ntuj Tim 30, 2016
Tus kws kho mob
P17-17 Addition of Drug Kisqali to the Self-Administered Oncology Prior Authorization with Quantity Limit Program
Hnub Tim pib siv tau lub khoos kas: Lub Plaub Hlis Ntuj Tim 28, 2017
Tus kws kho mob
P22-17 Identified Claims Processing Issues Grid
Hnub Tim pib siv tau lub khoos kas: Lub Tsib Hlis Ntuj Tim 10, 2017
Tus kws kho mob
P35-16 Requirement to Submit National Drug Codes and Related Information
Hnub Tim pib siv tau lub khoos kas: Lub Xya Hli Ntuj Tim 27, 2016
Tus kws kho mob
P27-16 Changes to Prior Authorization Requirements for Select Services for Commercial Products
Hnub Tim pib siv tau ntawm lub khoos kas: Rau Hlis Ntuj Tim 08, 2016
Tus kws kho mob
P15-16 Place of Service 53 will be Changed to a Facility Place of Service
Hnub Tim pib siv tau lub khoos kas: Lub Plaub Hlis Ntuj Tim 07, 2016
Tus kws kho mob
P20-16 Addition of Uptravi ® and Adempas ® to Existing Drug-Related Prior Authorization Program
Hnub Tim pib siv tau lub khoos kas: Lub Tsib Hlis Ntuj Tim 04, 2016
Tus kws kho mob
P10-16 New Drug-Related Prior Authorization Criteria for Gattex
Hnub Tim pib siv tau lub khoos kas: Lub Ob Hlis Ntuj Tim 08, 2016